Compare Pfizer Inc (PFE) vs Unilever plc (UL) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Unilever (UL) trades at $60.79, down 2.56% today, with a mixed technical and fundamental backdrop. The stock shows a bullish technical signal from moving averages but has missed earnings expectations in recent quarters. Revenue in 2024 was $60.76B with a net income margin of 9.45%, while the company explores strategic moves like a potential bid for Thorne and a partnership with Accenture to scale AI in manufacturing.

The outlook is balanced; strong cash flow and a high ROE of 53.32% support the dividend, but recent earnings misses and a high P/B ratio of 7.55 pose risks. Analyst sentiment is neutral with a 51.36% hold rating, reflecting cautious optimism amid execution challenges and macroeconomic headwinds.